[EN] HETEROCYCLIC KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE HÉTÉROCYCLIQUES
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2016022312A1
公开(公告)日:2016-02-11
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
disubstituted phenylpyridine derivatives was synthesized and their antiarrhythmic effects against chloroform-induced ventricular arrhythmias in mice were examined. Among them, 2- and 3-[2-(3-aminobutyramido)-4-(2,2,2-trifluroethoxy)phenyl]pyri dines (23h, 24h) and 3-[2-(3-aminobutyramido)-4-ethoxyphenyl]pyridine (24i) showed potent antiarrhythmicactivity. They had approximately twice the potency of mexiletine
5-(Pyridinyl)-benzoxazol-2(3H)-ones and their use as cardiotonics
申请人:Sterling Drug Inc.
公开号:US04310531A1
公开(公告)日:1982-01-12
5-PY-benzoxazol-2(3H)-ones, cardiotonic agents, are prepared by reacting 2-amino-4-PY-phenol with a carbonylating agent, e.g., carbonyldiimidazole, where PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents. 5-PY-benzoxazol-2(3H)-ones or pharmaceutically-acceptable acid-addition or cationic salts thereof are disclosed as active components in cardiotonic compositions for increasing cardiac contractility and in the method for increasing cardiac contractility in a patient requiring such treatment.
2-Amino-3(4 or 5)-(pyridinyl)phenols and their use as cardiotonics
申请人:Sterling Drug Inc.
公开号:US04297363A1
公开(公告)日:1981-10-27
2-Amino-3(4 or 5)-PY-phenol, a cardiotonic agent, is prepared by reducing 2-nitro-3(4 or 5)-PY-phenol, where PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents. 2-Amino-3(4 or 5)-PY-phenol or pharmaceutically-acceptable acid-addition salt thereof is disclosed as the active component in a cardiotonic composition for increasing cardiac contractility and in the method for increasing cardiac contractility in a patient requiring such treatment. The novel isomeric 4-amino-5-(4-pyridinyl)phenol is shown for comparative purposes.
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.